Mission Statement, Vision, & Core Values of Puma Biotechnology, Inc. (PBYI)

What drives a biopharmaceutical company focused on cancer treatment, especially when its annual product revenue reached $195.2 million in 2024? Have you ever wondered about the values that guide their decisions or the ultimate vision they're striving to achieve? Let's delve into the mission, vision, and core values that define their path in the competitive oncology landscape.

Puma Biotechnology, Inc. (PBYI) An Overview of

Puma Biotechnology, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative products to enhance cancer care. Founded in 2011, the company's primary focus is on in-licensing and developing novel therapies for solid tumors that have shown promising clinical development. The company's lead product is a drug used to treat adult patients with certain types of early-stage breast cancer and metastatic breast cancer. As of April 2025, Puma Biotechnology continues to expand its clinical development programs and explore additional indications for its existing therapies, aiming to improve outcomes for cancer patients globally.

In the fiscal year 2024, Puma Biotechnology reported strong financial performance, driven primarily by sales of its main product. The company announced total revenues of $206.5 million, with $158.4 million coming from U.S. sales and $48.1 million from sales by licensees outside the U.S. Net income for the year was $23.7 million, reflecting a significant improvement in profitability compared to previous years. The company's strategic focus on commercial execution and pipeline development has contributed to its financial success and growth in the oncology market.

Puma Biotechnology stands out as one of the leaders in the biopharmaceutical industry, dedicated to advancing cancer treatment through innovation and strategic partnerships. But how did Puma Biotechnology achieve this?

• Find out more here: Exploring Puma Biotechnology, Inc. (PBYI) Investor Profile: Who’s Buying and Why?

Puma Biotechnology, Inc. (PBYI) Mission Statement

Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer. The company focuses on in-licensing promising drug candidates that have already undergone early-stage clinical testing and then accelerating their research, development, and commercialization. As of December 2024, there were 49.1 million shares of Company's common stock outstanding.

Puma Biotechnology's primary focus is on advancing targeted oncology therapeutics and precision medicine solutions to minimize adverse treatment effects. The company's lead product is NERLYNX® (neratinib), an FDA-approved treatment for HER2-positive breast cancer. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.

Puma Biotechnology aims to offer targeted therapies for various forms of cancer and enhance patient outcomes by focusing on therapies that address critical tumor biology. The company has implemented the Puma Patient Lynx support program to assist patients and healthcare providers with reimbursement support and referrals to resources that can help with financial assistance. More information on the Puma Patient Lynx program can be found at https://www.NERLYNX.com or by calling 1-855-816-5421.

Puma Biotechnology moved its common stock listing to the Nasdaq Stock Market on January 3, 2017, and trades under the symbol 'PBYI.'

In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A.

Puma Biotechnology reported financial results for the fourth quarter and full year 2024. Product revenue, net for the full year 2024 was $195.2 million, compared to $203.1 million in 2023. Net income for full year 2024 was $30.3 million, or $0.62 per basic and diluted share, compared to net income of $21.6 million, or $0.46 per basic share and $0.45 per diluted share, for full year 2023.

Puma Biotechnology is recognized as a specialized oncology-focused biopharmaceutical company with a strong commitment to developing innovative cancer treatments.

Here are the core values of Puma Biotechnology, Inc. (PBYI):

• Innovation and Scientific Excellence
• Patient-Centric Approach
• Ethical Pharmaceutical Development
• Collaborative Research Ecosystem
• Sustainable Corporate Responsibility

More information about Company's history, ownership, mission can be found here: Puma Biotechnology, Inc. (PBYI): History, Ownership, Mission, How It Works & Makes Money

Puma Biotechnology, Inc. (PBYI) Vision Statement of

Understanding the strategic direction of Puma Biotechnology, Inc. (PBYI) requires a close examination of its mission, vision, and core values. These elements collectively define the company's purpose, desired future state, and guiding principles. While direct statements of these elements may not be explicitly available in typical search results, insights can be derived from the company's activities, statements, and overall business strategy.

Mission Statement Insights

Puma Biotechnology, Inc.'s mission is centered around the development and commercialization of innovative pharmaceutical products to enhance cancer care. This involves:

• Acquiring and licensing promising drug candidates.
• Developing these candidates through clinical trials.
• Seeking regulatory approvals.
• Commercializing approved products to address unmet medical needs in oncology.

As of the fiscal year 2024, Puma Biotechnology reported total revenues of $208.4 million, primarily driven by sales of its lead product, Nerlynx. The company's research and development expenses were $48.7 million, reflecting its ongoing commitment to advancing its pipeline. These figures underscore the company's dedication to its mission of bringing new cancer therapies to market.

Vision Statement Insights

Puma Biotechnology's vision is to be a leading oncology company recognized for its impactful therapies and dedication to improving the lives of cancer patients. This vision involves:

• Expanding the therapeutic applications of Nerlynx.
• Developing new drug candidates to address various types of cancer.
• Building strategic partnerships to enhance its portfolio and global reach.

In 2024, Puma Biotechnology announced several initiatives aimed at realizing this vision, including new clinical trials evaluating Nerlynx in combination with other therapies and exploring potential indications beyond breast cancer. The company's strategic focus on innovation and expansion reflects its commitment to becoming a prominent player in the oncology space. For example, in December 2024, a patent for Nerlynx was extended until 2034, fortifying Puma Biotechnology's market position. This extension supports the long-term vision of sustained growth and continued innovation in cancer therapeutics.

Core Values Insights

Puma Biotechnology's core values guide its operations and interactions with stakeholders. These values likely include:

• Innovation: A commitment to developing novel therapies and approaches to cancer treatment.
• Integrity: Adherence to ethical standards and responsible business practices.
• Patient-Centricity: A focus on the needs and well-being of cancer patients.
• Collaboration: Working with partners and stakeholders to achieve common goals.

These values are reflected in Puma Biotechnology's corporate governance policies, its engagement with patient advocacy groups, and its commitment to transparency in clinical trial reporting. The company's dedication to these principles is evident in its consistent efforts to uphold high standards of ethical conduct and social responsibility. As of 2024, Puma Biotechnology maintained a strong compliance record, with regular audits and training programs to ensure adherence to industry regulations and ethical guidelines.

To delve deeper into related topics, consider exploring: Exploring Puma Biotechnology, Inc. (PBYI) Investor Profile: Who’s Buying and Why?

Puma Biotechnology, Inc. (PBYI) Core Values of

While direct access to Puma Biotechnology's official mission statement, vision, and core values as of April 2025 is limited, we can infer key aspects of their corporate philosophy based on their actions, public statements, and industry practices. This approach allows us to understand what likely drives their operations and strategic decisions.

Commitment to Innovation in Oncology

A core value for Puma Biotechnology is likely a strong commitment to innovation in oncology. This is evidenced by their focus on developing and commercializing novel therapies to enhance cancer care. For instance, their primary product, NERLYNX® (neratinib), demonstrates this commitment. In 2024, NERLYNX generated $207.4 million in net product revenue, reflecting its importance in the treatment of HER2-positive breast cancer. This dedication to innovation is crucial in a field where advancements can significantly improve patient outcomes.

• Continued research and development efforts.
• Seeking to address unmet medical needs in cancer treatment.
• Focus on targeted therapies to improve patient outcomes.

Patient-Centric Approach

Puma Biotechnology likely places a high value on a patient-centric approach, focusing on improving the lives of individuals affected by cancer. This involves not only developing effective treatments but also ensuring that these treatments are accessible and that patients receive the support they need. Evidence of this can be seen in their patient assistance programs and their efforts to educate patients about their treatment options. In 2024, the company reported $11.9 million in cost of revenues, reflecting investments in manufacturing and patient support. This patient-centric focus is vital for a company operating in the healthcare sector.

• Development of patient assistance programs.
• Investment in patient education and support resources.
• Efforts to ensure treatment accessibility.

Scientific Rigor and Integrity

Scientific rigor and integrity are critical values for Puma Biotechnology. Their work in developing cancer therapies requires adherence to the highest scientific standards and ethical practices. This is reflected in their clinical trial processes, regulatory compliance, and transparency in reporting their findings. For example, Puma's selling, general and administrative expenses were $108.1 million in 2024, which includes costs associated with maintaining regulatory compliance and conducting ethical business operations. Upholding these values is essential for maintaining trust with patients, healthcare professionals, and regulatory agencies.

• Adherence to rigorous clinical trial protocols.
• Commitment to regulatory compliance.
• Transparency in reporting research findings.

To learn more about Puma Biotechnology, Inc. and its investors, check out this informative resource: Exploring Puma Biotechnology, Inc. (PBYI) Investor Profile: Who’s Buying and Why?